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Spatiotemporal control of drug delivery is important for a number of medical applications and may be achieved using polymersome
nanoparticles (PMs). Wnt signalling is a molecular pathway activated in various physiological processes, including bone repair, that requires
precise control of activation. Here, we hypothesise that PMs can be stably loaded with a small moleculeWnt agonist, 6-bromoindirubin-3′-oxime
(BIO), and activate Wnt signalling promoting the osteogenic differentiation in human primary bone marrow stromal cells (BMSCs). We showed
that BIO-PMs induced a 40% increase inWnt signaling activation in reporter cell lineswithout cytotoxicity induced by freeBIO.BMSCs incubated
with BIO-PMs showed a significant up-regulation of the Wnt target gene AXIN2 (14 ± 4 fold increase, P b 0.001) and a prolonged activation of
the osteogenic gene RUNX2. We conclude that BIO-PMs could represent an innovative approach for the controlled activation ofWnt signaling for
promoting bone regeneration after fracture.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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3–5Controlled, spatiotemporal delivery of therapeutic molecules
is a major goal in medicine that may be achieved by the use of
nanosized carriers.1 Polymersomes (PMs) are an attractive
candidate delivery agent. They are vesicles formed by the
self-assembly of amphiphilic copolymers in aqueous solutions.2
PMs possess a hydrophilic core and an amphiphilic shell which
can accommodate a variety of hydrophilic and hydrophobic
molecules and drugs at high concentration. PMs can be
synthesised from a wide range of biodegradable polymers, and
may be engineered to release payloads in response toThe authors state that they have no conflict of interest.
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PMs can be composed entirely of polyethylene glycol (PEG) in
order to prolong their in vivo circulation time,6 and/or can be
coupled with cell or tissue targeting motifs.7,8 To date, the
majority of research on PMs as drug delivery vehicles has
focused on cancer chemotherapy, where there is a need to deliver
high concentrations of toxic and often highly water-insoluble
drugs selectively to tumours.9 Various studies have shown that
PMs can incorporate a wide variety of chemotherapeutic small
molecules.10,11 Very recently PMs have been shown to increaseed Kingdom, (Grant numberMR/J004103/1), WessexMedical Research, UoS
hancellor's award from Malaya University, Malaysia, awarded to TAN, and
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comparison to the albumin-bound formulation of paclitaxel
currently commercialized as Abraxane®.12 Building on these
encouraging results, there is emerging data supporting the utility
of PMs as drug delivery vehicles beyond oncology.13,14 These
studies open up the possibility of applications of PMs in disease
conditions where control over intracellular delivery, pharmaco-
kinetic profile, and spatiotemporal delivery are fundamentally
important.
We are investigating the notion that PMs might be exploited
for the spatiotemporally-controlled delivery of therapeutic
molecules to bone injury sites to promote fracture repair. Bone
fracture is a highly regulated, reparative process that involves a
sequence of distinct but overlapping physiological processes.15
Uncomplicated fractures generally heal well, but in some
circumstances - for example in high-energy fractures, or when
there is significant underlying pathology - fracture healing is
delayed or may not occur. Delayed or non-union fractures are a
significant clinical burden24,25 and new therapies are urgently
required, but there are currently no clinically-approved drugs
available for systemic administration that promote fracture
healing.17
The canonical (β-catenin-dependent) Wnt signalling pathway
is a highly conserved molecular pathway that in bone tissue plays
a fundamental role controlling bone homeostasis and repair,15
and it is an attractive drug target in this context. Several
Wnt-targeting drugs have shown exceptional promise in
increasing bone mass in patients with osteoporosis.18 However,
there is a paucity of evidence to suggest that these therapeutics
could be successful in fracture healing in humans. This may stem
from the pleiotropy of Wnt signalling – elevated Wnt signalling
can exert strongly stimulatory effects on bone fracture, but can
also inhibit bone healing if activation is not timed
appropriately.19,20 Furthermore, we recently demonstrated that
Wnt activation in bone stem cells can both promote and inhibit
osteogenic differentiation in a similar manner.21 For this reason,
it is likely that if Wnt signalling is to be exploited in fracture
healing, its activation must be spatially and temporally regulated.
Nanodelivery provides a potentially attractive answer to this
challenge. Previous work has indicated that Wnt3A protein can
be stably associated with nanosized liposomes and improve
bone healing,20 osseointegration22 and stem cell activation.23
The use of recombinant proteins as therapeutic agents however
has several disadvantages, including expense of production and
poor stability during storage or following administration.24 An
alternative approach is to exploit stable, inexpensive, synthetic
small molecules that activate Wnt signalling. Examples are
AZD 2858 and AR-28, small molecules that have been shown to
enhance bone mass25,26 and augment fracture repair27 in rats
and mice, or 6-bromoindirubin-3′-oxime (BIO), the adminis-
tration of which resulted in a significant increase in bone
trabecular number and thickness,28 as well as increased dentin
mineralization following injury in healthy mice.29 Nonetheless,
the clinical application of many of these molecules including
BIO is limited by poor solubility, bioavailability and cytotox-
icity at high concentrations.30
In this study, we hypothesized that encapsulation of BIO in
PMs would allow the activation of the Wnt pathway in acontrolled manner while reducing the cytotoxicity associated
with the delivery of high concentrations of BIO. We produced
PMs using polyethylene glycol- polycaprolactone (PEG-PCL)
block copolymer. Both PEG and PCL polymers are approved for
the use in clinic, therefore enabling rapid translational of research
findings. We provide evidence of encapsulation and retention of
a BIO in PMs and for a cell-protective function promoted by
drug encapsulation within PMs. Finally, we demonstrate BIO
loaded-PMs promote osteogenic differentiation in human
primary cells, findings that highlight the potential of this system
in regenerative medicine.Methods
Extended materials and methods can be found in the
Supplementary Data.Results
6-Bromoindirubin 3′-oxime (BIO) can be stably loaded in PCL-
PEG polymersomes
W e f i r s t l o a d e d P C L - P E G P M s w i t h
6-bromoindirubin-3′-oxime (BIO), an ATP-competitive inhibi-
tor of glycogen-synthase-kinase-3β (GSK-3β) by dissolving
BIO either in the organic solvent fraction or in the aqueous PBS
(Figure 1).
To differentiate these techniques, we termed these resulting
PM preparations ‘DMF-dissolved’ or ‘PBS-dissolved’
respectively.
PBS- and DMF-dissolved PMs (Figure 2, A) displayed
uniform size distributions of ~65 nm ± 18 nm and similar final
concentrations of 1.5 × 1013 PMs ml−1 as measured by
nanoparticle tracking analysis (NTA) (Figure 2, B). These sizes
were in good agreement with the hydrodynamic diameter
measured by dynamic light scattering (DLS) (~62 nm ± 22
nm) (Figure 2, C). Unloaded PMs were slightly smaller than
BIO-loaded PMs (~ 57 nm vs. ~62 nm, Figure 2, C and Table 1),
but this difference was not significant (P = 0.70). Neither were
there any significant differences in the charge of PMs, as
measured by ζ-potential (Table 1).
On storage of PMs for up to 14 days, minor (b10%) changes in
size were observed for empty or DMF-dissolved PMs (Figure 2,D).
In contrast, core-loaded PMs were unstable, with an increase in size
from65nm to210nmbetween7 and14days and concurrent increase
in the polydispersity index (PdI) (from 0.19 to 0.31, Figure 2, D).
Next, we quantified the amount of BIO loaded in the two
preparations following synthesis and purification using absorption
spectroscopy. BIO has absorbance peaks at 535 and 580 nm where
there is little interference from Rayleigh scattering from PMs
(Supplementary Figure 1,A).We used absorbance of BIO at 535 nm
to determine a standard curve for BIO (Supplementary Figure 1, B).
Following purification, comparable concentrations of BIO were
measured in bulk suspensions (15 × 1012 PMsml−1) of core-loaded
(187 ± 36 μM) and DMF-dissolved PMs (198 ± 32 μM). Based on
these data we estimated an encapsulation efficiency of ~90% for
both formulations. Finally, we measured the stability of the
Figure 1. Schematic summary. (A) Cartoon depicting the structure of a polymersome (PM) indicating the aqueous core and the hydrophobic shell. (B) Schematic
representation of the methodology used to load BIO in PMs after dissolving it into DMF or PBS. (C) Image summarizing the cell types and readout
methodologies used. BIO: 6-bromoindirubin 3′-oxime; DMF: dimethylformamide; PBS: phosphate buffered saline; PEG-PCL: Polyethylene glycol-polyca-
prolactone; PM: polymersome.
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continuous dialysis sink conditions (Figure 2, E). BIO association
with PMs was stable for 1–2 days with negligible release, after
which release occurred steadily with ~10 ± 1% lost at day 3, and
56.68 ± 2.5%ofBIO lost between day 3 and 5.After this period, the
residual BIO was slowly but constantly released from the PMs, as
demonstrated by the presence of 22.3 ± 4.2% and 12.3 ± 6.7% of
the original concentration loaded still present after 10 and 14 days,
respectively (Figure 2, E). In summary, these data illustrate that the
Wnt pathway agonist BIO can be loaded in PCL-PEG PMs at high
concentrations for time periods of up to 48 hours.
BIO-loaded PMs are taken up by Wnt reporter cells and bone
marrow stromal cells (BMSCs)
Then we investigated the internalization of PMs in
Wnt-responsive and functionally relevant cells.31 This relies on
the incorporation within PMs of self-quenched high concentra-
tion of fluorescein, which then becomes detectable following
release from nanoparticles (Figure 3, A).
After 24 hours of incubation with PMs, both 3T3 Leading
Light®Wnt reporter cells and bonemarrow stromal cells (BMSCs)
were positive for fluorescein as measured by microscopy,
indicating internalization of PMs and release of payload (Figure
3, B). To investigate the kinetics of PMs uptake by these two cell
types we used flow cytometry. Figure 3, C andD show that within
1 hour of incubation 100% of 3T3 cells are positive for fluorescein,
compared to 91% ± 11% of BMSCs. 100% positivity of BMSCsfor fluorescein was not reached until 3 hours (Figure 3, C and D).
We observed differences in the relative mean fluorescence
intensity of each cell line, indicating differential PM uptake
between cell types (Figure 3, E). There was also a difference in the
kinetics of uptake between cells. The time at which half-maximal
fluorescence intensity (τ1/2) was reached was ~1 hour for BMSCs
compared to ~2.5 hours for 3 T3 cells. Inclusion of BIO in
fluorescein-containing PMs did not affect the total number of cells
that became positive for fluorescein, but resulted in a decrease in
the mean cellular fluorescence of 10 ± 3% and 21 ± 2% for
reporter cells and BMSCs, respectively (Supplementary Figure 2).
Together this data indicate that PMs are rapidly taken up by 3T3
Wnt reporter cells and human BMSCs, that the payload is released
intracellularly, and that inclusion of BIO has a minor effect on the
degree of uptake.
BIO-PMs induce Wnt signalling in a dose-dependent manner
To determinewhether PM-deliveredBIOwas able to induceWnt
signalling we incubated reporter cells with PBS-, DMF-dissolved
PMs or free BIO for 24 hours and measured the level of Wnt
activation by luciferase production (Figure 4, A). Both PM
preparations induced Wnt signalling activation. Compared to free
BIO, which has a maximum activation at a concentration of ~5 μM,
DMF-dissolved PMs induced a maximum response at a factor of
0.46 ± 0.03 of the readout measured using 5 μM free BIO, while
PBS-dissolved PMs induced a maximal response at a factor of
0.15 ± 0.03 of free BIO. This was despite PBS- andDMF-dissolved
PMs contained comparable concentration of BIO (Figure 4, B).
Figure 2. Characterisation of polymersomes loaded with BIO. (A) Cartoon depicting the three different polymersome (PM) preparations (B) Concentration and
size measurement histogram from NTA of PBS- and DMF-dissolved PMs. (C) DLS histogram showing the hydrodynamic distribution in diameter of PBS- and
DMF-dissolved PMs, and empty PMs. (D) Graph showing the size stability in solution of PMs over the course of 14 days. (E) Plot depicting the release profile of
DMF-dissolved PMs over 20 days. Data presented as mean ± SD (n = 3).
1270 E. Scarpa et al / Nanomedicine: Nanotechnology, Biology, and Medicine 14 (2018) 1267–1277We also confirmed the stability of the association between BIO
and PMs. We ultracentrifuged DMF-dissolved PM suspensions to
separate the PMs from supernatant and demonstrated that the activity
of the preparation (i.e. the ability to induce the activation of the Wnt
pathway in reporter cells) was retained in the pellet fraction
consisting of PMs (~90%of the total activitymeasured) (Figure 4,C).
As suggested by data in Figure 2,E, we confirmed that the association
of BIO with PMs was stable for up to 36 hours. Continuous dialysis
under sink conditions did not diminish the activity of the PM-BIOpellet, with no activity lost to the supernatant or through the dialysis
tubing (Figure 4, D).
PM encapsulation protects cells from BIO-induced toxicity but
retains Wnt signalling activity
Although being an established inhibitor of GSK-3β,34 BIO is
relatively membrane impermeable. and its IC50 is ~5 nM for
GSK-3β. However, extracellular concentrations of 500–1000×
Table 1
Polymersome (PM) preparations over time.
PMs
Empty-PMs Core-BIO loaded PMs Shell-BIO loaded PMs
DH PdI ζ-potential DH PdI ζ-potential DH PdI ζ-potential
Day
1 56 ± 22 0.11 -5 ± 2.1 62 ± 25 0.19 −4 ± 2.7 63 ± 26 0.11 −6 ± 0.96
7 59 ± 22 0.11 65 ± 27 0.19 60 ± 21 0.14
14 60 ± 21 0.11 210 ± 50 0.31 62 ± 22 0.15
Summary of size, polydispersity index (PI) and ζ-potential of PBS- and DMF-dissolved PMs and empty-PMs over 21 days. Data presented as mean ± SD (n = 3).
PDI: polydispersity index; PM: polymersome.
Figure 3. Cellular uptake of fluorescein-loaded polymersomes (PMs). (A) Cartoon depicting the methodology used to assess cellular uptake of PMs using
fluorescein. When carrying a payload of fluorescein above the quenching concentration the PM is non-fluorescent. Upon cellular internalization payload release
can be visualized as the fluorescein disperses and falls below the quenching concentration. (B) Fluorescence imaging showing intracellular release of fluorescein
in 3 T3 Wnt reporter cells and human bone marrow stromal cells (BMSCs) incubated with fluorescein-PMs for 1 hour. (C) Representative flow cytometry
histogram of 3 T3 Wnt reporter cells and human BMSCs incubated for 1, 3, 6 or 24 hours with fluorescein-PMs. Both graphs show the progressive increase in
fluorescence intensity of cells treated with fluorescein-PMs compared to 99% of the control untreated cells (grey). Dotted lines indicate the markers set to
discriminate between positive and negative cells. (D) Graph depicting the progressive increase in the percentage of cells positive for fluorescein over-time. (E)
Graph depicting the progressive increase in the relative fluorescence intensity over-time. Data presented as mean ± SD (n = 3).
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the Wnt-signalling pathway (Figure 5, A).35 In parallel, BIO is
known to cause cytotoxicity by unknown mechanisms,35
probably through binding to other intracellular kinases such as
CDKs, JAK–STAT.36–38 We hypothesized that delivery of BIO
using PMs would reduce these non-specific effects through a
more controlled delivery.
To investigate this, we incubated 3T3 reporter cells with
increasing concentrations of either DMF-dissolved PMs (here-
after referred as to BIO-PMs) or free BIO and compared their
effects on activity and cell-induced toxicity. Free BIO promoted
Wnt signalling activity in a dose-dependent manner with a
maximal response at a concentration of 5 μM, and a progressive
decline at higher concentrations. The maximal activation of Wntsignalling using BIO-PMs was reached at a concentration of
15 × 1011 PMs ml−1, corresponding to 46 ± 3% of the maximal
activity measured using 5 μM BIO. Similar to free BIO, at
concentrations higher than 15 × 1011 PMs ml−1, BIO-PMs also
resulted in a decrease in reporter cell activity (Figure 5, A), albeit
less markedly than with free BIO. We found a dose-dependent
decrease in cell viability in response to free BIO (57 ± 10% of
cell survival at an extracellular concentration of 5 μM), but no
decrease in cell viability in response to BIO-PMs, even at
concentrations that induced a decline in pathway activation
(Figure 5, B and C). This suggests that in contrast to free BIO,
BIO-PMs at any extracellular concentration tested do not have
cytotoxic effect on cells. The decreased pathway activation at
high PM concentrations must therefore occur by non-cytotoxic
Figure 4. Stable encapsulation of BIO within polymersomes (PMs). (A) Overview of the luciferase assay used to assess activity of PMs loaded with BIO. After
incubation with either free BIO or loaded PMs, the small molecule inhibits GSK-3β in the cytosol allowing for the accumulation of β-catenin and, following
translocation to the nucleus, activation of the Wnt pathway. As a consequence of the activation of the pathway, the luciferase enzyme is synthesised. (B) Bar chart
showing the fold increase in Wnt signalling activation of 3 T3 luciferase reporter cells incubated for 24 hours with 15 × 1011 PMs ml−1 of PBS-, DMF-dissolved or
empty PMs, or 5 μM BIO (n = 9). (C) Bar chart showing the level of activity of DMF-dissolved PMs and either pellet or supernatant following ultracentrifugation
(n = 4). (D) Bar chart showing the unaltered relative activity of 3 T3 luciferase reporter cells incubated for 24 hours with BIO-PMs dialyzed for either 12, 24 or 36
hours (n = 5). In B, C & D values are normalized against untreated cells, and are expressed as relative activation of cells treated with 5 μMBIO for 24 hours. All the
data is presented as mean ± SD, one-way ANOVA, with Sidak's post-hoc correction, ****p b 0.0001. APC: adenomatous polyposis coli; BIO: 6-bromoindirubin
3′-oxime; DVL: dishevelled; GSK-3β: glycogen synthase kinase-3β; LEF: lymphoid enhancer factor; TCF: T-cell factor; β-cat: β-catenin.
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on free-BIO induced Wnt pathway activation, nor of increases in
PM PBS buffer solution (Supplementary Figure 3).
It is likely that the protection of cytotoxicity conferred by
encapsulation of BIO may result from an uptake route that
provides more specific delivery to its intended target. To
investigate this, we measured the temporal activation of Wnt
signalling in the reporter cell line by performing a pulse chase
experiment, where cells were exposed to either PMs or free BIO
for fixed periods of times, before wash-out and subsequent
assessment of pathway activation at 24 hours (Figure 5, E). In
order to compare free BIO and BIO-PMs, extracellular
concentrations were selected (i.e. final concentrations in the
cellular media) that elicit an equivalent activation of the Wnt
signalling pathway in a 24 hour activation experiment. These
concentrations were calculated from the experiments reported in
Figure 5, A and are 2 μM and 15 × 1011 mL−1 for free BIO and
BIO-PMs, respectively. As shown in Figure 5, F, the activity
measured was greater for free BIO than for BIO-PMs for short
exposure times (1–6 hours), but was similar at time periods of
b12 hours. Supporting this, at 48 hours post incubation,
BIO-PMs induced a significantly higher level of Wnt signalling
activation than 2 μM free BIO (Supplementary Figure 4,p b 0.05). These results suggest that free BIO enters cells
more quickly than BIO-PM and that BIO delivered by PMs
requires a longer period of time to accumulate and activate
signalling. Together these data indicate that BIO-PMs activate
Wnt signalling, are not cytotoxic, and allow for a time-controlled
delivery of high concentrations of payload, which would be
cytotoxic if administered in a ‘free’ form.
Application of BIO-PMs to achieve osteogenic priming of
human multipotent stromal cells
Activation of Wnt signalling is crucial in many repair
processes, including bone regeneration following injury. Multi-
potent BMSCs contribute to bone repair and their differentiation
to osteoblasts is known to be modulated by canonical Wnt
signalling21,23,39; therefore, they represent a good target for
assessing the biological activity of PM-mediated Wnt activation
(Figure 6, A).
Incubation of BMSCs with BIO-PMs resulted in a
significant increase in the expression of the Wnt target gene
AXIN2 at 24 hours (12 ± 6 fold increase, p b 0.001, for
6 × 1011 BIO-PMs ml−1 and 9 ± 3 fold increase, p b 0.05,
15 × 1011 BIO-PMs ml−1). Similarly, 2 μM free BIO also
Figure 5. Comparison of BIO-Polymersomes (PMs) vs. free BIO activity, induced cytotoxicity and kinetics. (A) Dot plot graph depicting the activity of 3T3
luciferase reporter cells incubated for 24 hours with increasing concentrations of either BIO-PMs (black) or free BIO (red). (n = 3). (B) Dot plot graph depicting
the progressive reduction in viability of 3 T3 luciferase reporter cells incubated for 24 hours with increasing concentrations of free BIO (red), whilst cells exposed
to BIO-PMs (black) were unaffected (n = 3). (C) Representative pictures of 3 T3 luciferase reporter cells treated with 15 × 1011 BIO-PMs ml−1. (D)
Representative pictures of 3 T3 luciferase reporter cells treated with 2 μM BIO. (E) Schematic representation of the time points investigated during the
pulse-chase experiments. (F) Dot plot graph of 3 T3 reporter cells activity after incubation with either BIO-PMs (15 × 1011 BIO-PMs ml−1, black) or 2 μMBIO
(red) for increasing time periods (1, 2, 3, 6, 12 or 24 hours), (n = 3). All the data is presented as mean ± SD. Values are normalized against untreated cells, and
are expressed as relative activation of cells treated with 5 μM BIO for 24 hours.
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p b 0.001). However, BIO-PMs promoted a sustained activa-
tion of Wnt signalling compared to free BIO (p b 0.0001),
before declining to baseline levels or lower after 4 days (Figure
6, B). These data indicate that BIO-PMs are internalized by
BMSCs and that BIO-PMS promote a prolonged activation of
the Wnt signalling pathway.Next, we investigated whether the activation of Wnt induced by
BIO-PMswould also promote osteogenic differentiation of BMSCs.
As shown in Figure 6,C, the osteogenic ‘master gene’ RUNX2, was
markedly up-regulated following 24 hour treatment with BIO-PMs
(more than 1.5 fold increase compared to control), and significantly
increased after incubation with 2 μM BIO (2.5 ± 0.5 fold increase
compared to control, p b 0.05). Importantly, incubation of BMSCs
Figure 6. BIO-polymersomes promote osteogenic commitment of human bone marrow stromal cells (BMSCs). (A) Cartoon depicting the genes investigated. (B)
Relative expression of AXIN2 in BMSCs incubated for 24, 48 or 96 hours with either BIO-PMs (6 × 1011 or 15 × 1011 BIO PMs ml−1) or 2 μM BIO, (n = 3).
(C) mRNA expression of RUNX2 in BMSCs incubated for 24 or 96 hours with either BIO-PMs (6 × 1011 or 15 × 1011 BIO PMs ml−1) or 2 μM BIO, (n = 3).
(D) Relative fold expression of SP7 in BMSCs incubated for 24 or 96 hours with either BIO-PMs (6 × 1011 or 15 × 1011 BIO PMs ml−1) or 2 μM BIO. Values
are normalized against housekeeping gene GAPDH and are expressed as fold difference compared to untreated cells. All the data is presented as mean ± SD and
analyzed with two-way ANOVA, ****p b 0.0001, ***p b 0.001.
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a prolonged up-regulation of RUNX2, as evidenced by the gene
expression 4 days post exposure (2.3 ± 0.96 fold increase compared
to control, p b 0.05) (Figure 6,C). Similar to free BIO incubation of
BMSCswithBIO-PMs also promoted the up-regulation ofSP7 (also
known as Osterix), which is another key gene involved in the
osteogenic commitment (Figure 6, D). Together this data indicates
that BIO-PMs activate Wnt signalling in human BMSCs and
promote their initial osteogenic commitment.Discussion
Polymeric nanoparticles have potential for drug delivery
where spatiotemporal delivery of a drug is key. Canonical Wnt
signalling in bone repair is one such example. In this study, we
have demonstrated that; (i) PMs can carry high concentrations of
a relatively water-insoluble activator of Wnt signalling, (ii) PMs
are taken up by cells important in the bone reparative process,
and (iii) that activation of canonical Wnt signalling and
osteogenic differentiation can be achieved while avoiding the
toxicity that BIO causes when delivered with no carrier.
In cases of severe fractures, a pharmacological treatment
aimed to promote bone repair could be beneficial in order to limitthe incidence non-healing fractures. It is estimated that 10% to
50% of all the fractures diagnosed, depending on their
anatomical localization, will not heal adequately, resulting in
what is defined as ‘non-union’.16,40 Currently, bone morphoge-
netic proteins (BMPs) are the only growth factors approved for
aiding fracture healing.41 However, there are several limitations
when using BMPs in clinic, including osteolysis, soft tissue
swelling, ectopic bone formation due to the use of supra-
physiological doses, and the high cost of the drug.42 Wnt could
therefore be a more robust and reliable molecular target.
Encapsulation of Wnt agonist in a drug delivery system could
limit the off-target accumulation and dramatically reduce the
doses administered.
Liposomes loaded with Wnt proteins have been shown to be
effective in promoting bone repair following local
administration,20 and in inducing the osteogenic differentiation
of human skeletal stem cell populations.23 However, liposomes
are limited by short half-life in vivo44 and have a limited ability
to retain payloads.2 Conversely, PMs are able to protect the
payload from degradation in addition to high circulation half-life
and low off-site accumulation in vivo.12,45 PMs core-shell
structure allows for accommodation of hydrophilic and hydro-
phobic payloads simultaneously, including molecules soluble in
both phases. BIO is soluble in organic solvents (i.e. DMF) and in
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loaded with BIO by incorporating it either in the polymer/DMF
solution or in the PBS bath. In the PBS-dissolved preparation the
inclusion of BIO led to PM instability with changes in size 14
days post-production. An explanation for this observation is that
BIO precipitates out of solution within the PM core causing
perturbations to the PM structure and its premature collapse. The
final concentration of BIO encapsulated in the two preparations
was investigated using absorbance spectroscopy.47 This tech-
nique has inherent limitations including poor quantitative
sensitivity and may underestimate the final concentration of
BIO if any of it is in the solid state. Future studies using high
performance liquid chromatography will be needed to better
characterize BIO encapsulation.
We demonstrated that PMs are internalized by Wnt reporter
cells and that the presence of BIO does not affect cellular uptake.
Using a luciferase assay we have shown that DMF-dissolved
PMs were significantly more active than PBS-dissolved PMs.
This may be due to the fact that the 6 carbon atoms present in
PCL backbone structure create strong supramolecular hydro-
phobic interactions between the molecule and the polymer itself
when the two are dissolved in the same phase.48 Previous work
has demonstrated that the solubility of hydrophobic drugs within
a PM preparation is determined by the number of hydrogen
bonds between payload and polymer, and given a constant
concentration of drug, these bonds are directly proportional to
the number of PCL monomers present.49 This would also
explain the high level of association between BIO molecules and
PMs demonstrated by dialysis and ultracentrifugation.
Regardless of the mechanism by which BIO was incorporated
in PMs, drug release occurs rapidly following uptake, as
determined by Wnt reporter cell assays. It can be hypothesized
that hydrolytic processes taking place at the interface between
PEG and PCL50,51 would promote the progressive exposure of
BIO molecules to the extra-vesicular environment, which may
result in an increased gradient pressure with subsequent release
through diffusion.52
A concentration of 15 × 1011 BIO-PMs ml−1 and an
extracellular concentration of 2 μM BIO induced similar levels
of Wnt signalling activation in reporter cells, which was
approximately ~40% of the maximal activation measured
(following incubation with an extracellular concentration of 5
μM BIO). The relationship between concentration of BIO-PMs
used and intensity of Wnt signalling measured was biphasic,
similar to that observed with free BIO. However, the two
conditions had the opposite effect on cellular viability. High
concentrations of free BIO were cytotoxic for the reporter cells,
in line with previous observations on several cancer cells.36,38,46
In contrast, incubation with BIO-PMs did not induce cellular
toxicity indicating that intracellular delivery using PMs avoids
the activation of molecular pathways that are switched on when
BIO is delivered in its free form, or PMs may mediate a
protective action that inhibits BIO cytotoxicity. This may be
mediated by the slow release of the payload into the cytoplasm.
Pulse-chase experiments suggested that maximal activation of
the Wnt pathway following incubation with BIO-PMs is delayed
compared to free BIO. It has been demonstrated that intact
PEG-PCL nanoparticles are still present intracellularly 24 hoursafter their initial cellular internalisation.53 These data suggest
that PMs could function as intracellular depot of payloads50 and
may explain the protective mechanism mediated by PMs. If it is
assumed that BIO cytotoxicity is induced by the total inhibition
of one of the CDKs,38 it is possible that the high intracellular
concentration of free BIO is inhibiting the kinase at any given
time, while the slow release from PMs is sufficient to transiently
inhibit the kinase, but not enough to prevent its reactivation over
time resulting in the absence of cytotoxicity. Furthermore, the
depot effect mediated by PMs is induces a sustained activation of
the Wnt signalling pathway over the course of 48 hours. A
limitation of these findings is that the level of activity recorded
using the reporter cells is a reflection of the amount of functional
luciferase enzyme produced, and the luciferase readout can be
significantly affected by a number of factors (i.e. the number of
empty-PMs present in solution). In order to overcome these
limitations, it would be important to quantify the intracellular
concentration of BIO at different time points following
incubation with either free BIO or BIO-PMs. For example, in
future experiments it would be useful to create isotope-labeled
variants of both BIO and PEG-PCL copolymer in order to be able
to accurately quantify their concentration within the cells after
uptake.
Finally, we investigated the application of BIO-PMs as
possible source of controlled Wnt signalling activation for
therapeutic purposes. First, we demonstrated that BIO-PMs are
internalized by BMSCs inducing increased expression of AXIN2,
which demonstrates the activation of the Wnt pathway. The
results obtained with BMSCs corroborated what observed in the
reporter cells, whereby BIO-PMs induce the maximal activation
of the Wnt pathway after a 48 hour incubation, reinforcing the
hypothesis that PMs function as intracellular depot for BIO.
Secondly, we demonstrated the increased relative expression of
both RUNX2 and SP7 following incubation with BIO-PMs.
These genes are involved in the early osteogenic differentiation
of BMSCs.54 This is in agreement with previous studies.55,56
Very recently, Low and colleagues demonstrated that micelles
loaded with BIO and tethered with a bone-targeting peptide were
able to increase both bone mineral density and bone volume in
mice models of bone fracture.57 Future studies will address the
functionality of BIO-loaded PMs in augmenting bone repair
following fracture. Nevertheless, it was demonstrated that PMs
could be loaded with BIO and induce significant activation of the
Wnt signalling pathway following incubation with either reporter
cells or BMSCs. There has not been previous research
demonstrating the encapsulation of a GSK-3b inhibitor in PMs,
making the results here especially novel.
In summary, the results presented demonstrate that PMs
loaded with BIO can induce the activation of the Wnt signalling
pathway. This encapsulation of a small molecule into PMs
results in reduced cytotoxicity and in sustained Wnt signalling
activation that promotes the early osteogenic differentiation of
human stem cells. In view of the continuous advances in
polymer chemistry and nanoparticle formulations,58 we dem-
onstrated that “basic” PEG-PCL PMs incorporating a commer-
cially available small molecule, may be a simple good candidate
for a therapeutic approach focused on promoting bone
regeneration following injury.
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Supplementary data to this article can be found online at
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